
Traditional immunotherapies have limited efficacy in treating solid tumors, necessitating more effective strategies. A recent Viewpoint study highlights qualitative aspects of neoantigen-based therapy. The study emphasizes the differentiation between private and recurrent neoantigens, the significance of neoantigen clonality, and introduces new neuropeptide subtypes that enhance the potential of neoantigens in immunotherapy. These insights may pave the way for improved treatments targeting malignant tissue.
Like
Save
Share